Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs JPMorgan Equity Premium Income ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 7.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and JPMorgan Equity Premium Income ETF for 56 Days on average.
| IOVA | JEPI | |
|---|---|---|
Market Cap | $6.04B | $45.55B |
Volume | 14,805,993 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $14.82 | $59.88 |
52-Week Low | $1.81 | $55.29 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPI trades at $56.73, up 0.5% with a bearish technical signal from moving averages. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and July 2026. Technical indicators show neutral oscillators with key support at $56 and resistance at $57. Recent news highlights JEPI's role in income strategies and institutional interest.
The covered-call strategy provides income but may limit upside during rallies. Institutional ownership growth signals confidence, though the bearish technical outlook and income-focused strategy suggest moderate growth potential with steady dividend income as the primary appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
